181 related articles for article (PubMed ID: 9436085)
1. Ethical and legal aspects of teratogenic medications: the case of isotretinoin.
Moskop JC; Smith ML; De Ville K
J Clin Ethics; 1997; 8(3):264-78. PubMed ID: 9436085
[No Abstract] [Full Text] [Related]
2. Isotretinoin prescribing: finding a balance between benefit and risk.
Stern RS
Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):611-3. PubMed ID: 16134100
[No Abstract] [Full Text] [Related]
3. The use of Food and Drug Administration--approved medications for unlabeled (off-label) uses. The legal and ethical implications.
Torres A
Arch Dermatol; 1994 Jan; 130(1):32-6. PubMed ID: 8285737
[TBL] [Abstract][Full Text] [Related]
4. Silence is not always golden in medical decision-making.
Paris JJ; Moreland MP
Am J Bioeth; 2007 Jul; 7(7):39-40. PubMed ID: 17654383
[No Abstract] [Full Text] [Related]
5. Silent decisions or veiled paternalism? Physicians are not experts in judging character.
Kon AA
Am J Bioeth; 2007 Jul; 7(7):40-2. PubMed ID: 17654384
[No Abstract] [Full Text] [Related]
6. FDA, Roche to implement new dispensing procedures for isotretinoin.
Young D
Am J Health Syst Pharm; 2001 Dec; 58(24):2359-60. PubMed ID: 11794946
[No Abstract] [Full Text] [Related]
7. Responses to open peer commentaries on "Physicians' silent decisions: because patient autonomy doesn't always come first".
Whitney SN; McCullough LB
Am J Bioeth; 2007 Jul; 7(7):W1-3. PubMed ID: 17654368
[No Abstract] [Full Text] [Related]
8. Court-ordered treatment in obstetrics: the ethical views and legal framework.
Chervenak FA; McCullough LB
Obstet Gynecol; 1992 Mar; 79(3):476-7; author reply 478-9. PubMed ID: 1738534
[No Abstract] [Full Text] [Related]
9. Accutane-exposed pregnancies--California, 1999.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2000 Jan; 49(2):28-31. PubMed ID: 10680601
[TBL] [Abstract][Full Text] [Related]
10. How to ensure fetal safety when mothers use isotretinoin (Accutane).
Koren G; Pastuszak A
Can Fam Physician; 1997 Feb; 43():216-9. PubMed ID: 9040906
[No Abstract] [Full Text] [Related]
11. Women in early phase trials: an IRB's deliberations.
Anderson JR; Schonfeld TL; Kelso TK; Prentice ED
IRB; 2003; 25(4):7-11. PubMed ID: 14649248
[No Abstract] [Full Text] [Related]
12. [Acne, hyperandrogenism and resistance to oral isotretinoin: 23 cases].
Faure M
Ann Dermatol Venereol; 1998 Jul; 125(6-7):431-2. PubMed ID: 9747303
[No Abstract] [Full Text] [Related]
13. Relapse of acne following isotretinoin treatment: a retrospective study of 405 patients.
Liu A; Yang DJ; Gerhardstein PC; Hsu S
J Drugs Dermatol; 2008 Oct; 7(10):963-6. PubMed ID: 19112761
[TBL] [Abstract][Full Text] [Related]
14. Ethical considerations.
Treiman DM
Epilepsy Res Suppl; 1993; 10():137-48. PubMed ID: 8251089
[No Abstract] [Full Text] [Related]
15. The threat of the new managed practice of medicine to patients' autonomy.
Chervenak FA; McCullough LB
J Clin Ethics; 1995; 6(4):320-3. PubMed ID: 8750591
[No Abstract] [Full Text] [Related]
16. Accutane risk management program strengthened.
FDA Consum; 2002; 36(1):8. PubMed ID: 11881607
[No Abstract] [Full Text] [Related]
17. [Can be treated with isotretinoin patients with acne and Gilbert's syndrome?].
Suárez Crespo JF; García Mellado V; Becerra Massare P; Martín-Vivaldi Martínez R
Rev Esp Enferm Dig; 1996 Aug; 88(8):584-5. PubMed ID: 8962771
[No Abstract] [Full Text] [Related]
18. Continued occurrence of Accutane-exposed pregnancies.
Honein MA; Paulozzi LJ; Erickson JD
Teratology; 2001 Sep; 64(3):142-7. PubMed ID: 11514944
[TBL] [Abstract][Full Text] [Related]
19. The cost of clear skin: balancing the social and safety costs of iPLEDGE with the efficacy of Accutane (isotretinoin).
Doshi A
Seton Hall Law Rev; 2007; 37(2):625-60. PubMed ID: 17294569
[No Abstract] [Full Text] [Related]
20. Management of adult acne and acne variants.
Cunliffe WJ
J Cutan Med Surg; 1998 May; 2 Suppl 3():7-13. PubMed ID: 9873117
[No Abstract] [Full Text] [Related]
[Next] [New Search]
